Table 2.
Results of univariate and multivariate analyses for the associations between potential risk factors and biochemical failure
| Potential Risk Factors | Biochemical Failure − (n = 103) |
Biochemical Failure + (n = 24) |
Univariate Analysis |
Multivariate Analysis |
|
|---|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | |||
| Pretreatment PSA Level | 0.002 | - | NS | ||
| <10 ng/mL | 73 (70.9%) | 11 (45.8%) | |||
| ≥10 ng/mL | 30 (29.1%) | 13 (54.2%) | |||
| Age | 0.218 | - | NS | ||
| <70 y | 53 (51.5%) | 9 (37.5%) | |||
| ≥70 y | 50 (48.5%) | 15 (62.5%) | |||
| Tumor Stage | 0.131 | - | NS | ||
| T1b-T1c | 52 (50.5%) | 7 (29.2%) | |||
| T2a | 34 (33%) | 14 (58.3%) | |||
| T2b | 11 (10.7%) | 2 (8.3%) | |||
| T2c | 6 (5.8%) | 1 (4.2%) | |||
| Gleason Score | 0.632 | - | NS | ||
| ≤6 | 14 (13.6%) | 2 (8.3%) | |||
| 7 (3 + 4) | 21 (20.4%) | 3 (12.5%) | |||
| 7 (4 + 3) | 32 (31%) | 8 (33.3%) | |||
| ≥8 | 36 (35%) | 11 (45.9%) | |||
| % Positive Biopsy Cores | 0.675 | - | NS | ||
| <50% | 69 (67%) | 15 (62.5%) | |||
| ≥50% | 34 (33%) | 9 (37.5%) | |||
| Perineural Invasiona | 0.086 | - | NS | ||
| Positive | 59/82 (72%) | 11/21 (52.4%) | |||
| Negative | 23/82 (28%) | 10/21 (47.6%) | |||
| Risk classificationb | 0.033 | 3.9 (1.4-10.8) | 0.007 | ||
| Intermediate 1 NCCN risk factor | 50 (48.5%) | 5 (20.8%) | |||
| Intermediate >1 NCCN risk factor | 14 (13.6%) | 6 (25%) | |||
| High-risk | 39 (37.9%) | 13 (54.2%) | |||
| PSA Nadira | < 0.001 | 5.5 (2.3-12.9) | < 0.001 | ||
| <1 ng/mL | 83/96 (86.5%) | 12/23 (52.2%) | |||
| ≥1 ng/mL | 13/96 (13.5%) | 11/23 (47.8%) | |||
CI = confidence interval, HR = hazard ratio, NCCN = National Comprehensive Cancer Network; NS = non-significant; PSA = prostate-specific antigen.
a
Not available for all patients. Group denominators are shown.
b
Intermediate >1 NCCN risk factor and high-risk patients were analyzed combined.